Modulation of Intrinsic P-glycoprotein Expression in Multicellular Prostate Tumor Spheroids by Cell Cycle Inhibitors
Overview
Biophysics
Affiliations
The effects of cell cycle inhibition on the expression of the multidrug resistance transporter P-glycoprotein (P-gp) as well as of the cyclin-dependent kinase (CDK) inhibitors p27(Kip1) and p21(WAF-1) were investigated in DU-145 prostate tumor spheroids. With increasing spheroid size the number of cells in the G0/G1 phase augmented, whereas the number of cells in the G2/M phase and the S phase of the cell cycle declined. The number of G0/G1 cells was elevated after incubation with either mimosine, staurosporine or serum-free medium. Mitomycin C and roscovitine increased the number of S phase cells. Roscovitine additionally increased cells in the G2/M phase. Incubation in serum-free medium upregulated p21(WAF-1), p27(Kip1) and P-gp. Mimosine treatment resulted in upregulation of p27(Kip1) and P-gp, whereas p21(WAF-1) remained unchanged. Upon roscovitine treatment p27(Kip1) and p21(WAF-1) were downregulated, whereas P-gp was unaltered. Mitomycin C treatment resulted in downregulation of p27(Kip1) and p21(WAF-1); no significant change in P-gp levels was observed. Staurosporine induced upregulation of p21(WAF-1) whereas p27(Kip1) remained unaltered. P-gp was downregulated upon staurosporine treatment, which was owing to an elevation of intracellular reactive oxygen species by this compound. It is concluded that upregulation of P-gp in G0/G1 phase cells requires coexpression of the CDK inhibitor p27(Kip1) but not the CDK inhibitor p21(WAF-1).
Three-Dimensional Cell Cultures as an In Vitro Tool for Prostate Cancer Modeling and Drug Discovery.
Fontana F, Raimondi M, Marzagalli M, Sommariva M, Gagliano N, Limonta P Int J Mol Sci. 2020; 21(18).
PMID: 32948069 PMC: 7554845. DOI: 10.3390/ijms21186806.
Wu J, Cang S, Liu C, Ochiai W, Chiao J Exp Hematol Oncol. 2020; 9:12.
PMID: 32537260 PMC: 7288500. DOI: 10.1186/s40164-020-00168-0.
Krawczenko A, Bielawska-Pohl A, Wojtowicz K, Jura R, Paprocka M, Wojdat E PLoS One. 2017; 12(2):e0172371.
PMID: 28212450 PMC: 5315393. DOI: 10.1371/journal.pone.0172371.
Barrera-Rodriguez R, Fuentes J Cancer Cell Int. 2015; 15:47.
PMID: 26221079 PMC: 4517505. DOI: 10.1186/s12935-015-0200-6.
Sarisozen C, Abouzeid A, Torchilin V Eur J Pharm Biopharm. 2014; 88(2):539-50.
PMID: 25016976 PMC: 4252620. DOI: 10.1016/j.ejpb.2014.07.001.